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Abstract Vaccinations and infections are possible trig-
gers of Guillain-Barre´ syndrome (GBS). However, studies
on GBS after vaccinations during the influenza
A(H1N1)pmd09 pandemic in 2009, show inconsistent re-
sults. Only few studies have addressed the role of influenza
infection. We used information from national health data-
bases with information on the total Norwegian population
(N = 4,832,211). Cox regression analyses with time-
varying covariates and self-controlled case series was ap-
plied. The risk of being hospitalized with GBS during the
pandemic period, within 42 days after an influenza diag-
nosis or pandemic vaccination was estimated. There were
490 GBS cases during 2009–2012 of which 410 cases oc-
curred after October 1, 2009 of which 46 new cases oc-
curred during the peak period of the influenza pandemic.
An influenza diagnosis was registered for 2.47 % of the
population and the vaccination coverage was 39.25 %. The
incidence rate ratio of GBS during the pandemic peak
relative to other periods was 1.46 [95 % confidence inter-
val (CI) 1.08–1.98]. The adjusted hazard ratio (HR) of GBS
within 42 days after a diagnosis of pandemic influenza was
4.89 (95 % CI 1.17–20.36). After pandemic vaccination the
adjusted HR was 1.11 (95 % CI 0.51–2.43). Our results
indicated that there was a significantly increased risk of
GBS during the pandemic season and after pandemic in-
fluenza infection. However, vaccination did not increase
the risk of GBS. The small number of GBS cases in this
study warrants caution in the interpretation of the findings.
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Introduction
Guillain-Barre´ syndrome (GBS) is a rare but serious dis-
ease in which the immune system attacks nerve cells,
causing muscle weakness, paralysis, and in some cases,
death [1]. The causal mechanisms of GBS are not fully
known, but GBS may be triggered by infectious illnesses,
and vaccinations and influenza have been suggested as
potential triggers [2, 3]. However, studies on GBS after
influenza infection or vaccination show contradictory
results.
During the influenza outbreak in 1976–1977, an Amer-
ican study found an increased risk of GBS after influenza
vaccination [4]. Also, after the influenza A(H1N1)pmd09
pandemic in 2009, have several studies reported an asso-
ciation between H1N1 immunizations and GBS [5–7],
while other studies have not found any association [3, 8, 9].
Thus the role of vaccination as a possible trigger of GBS is
unclear. Following the 2009 pandemic, two international
collaborative efforts studied the role of vaccination on the
GBS [10, 11]. Results from these international studies were
also inconsistent; one study showed a significant asso-
ciation between influenza A(H1N1) vaccine (pH1N1) [10],
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while the other study reported that relative incidence of
GBS was not significantly elevated after pandemic vacci-
nation [11].
To our knowledge, only a few other studies have in-
vestigated the role of influenza infection in GBS, and as a
potential confounder of the association between vaccina-
tion and GBS [3, 12–14].
During the 2009 pandemic, an adjuvanted influenza
A(H1N1)pdm09 vaccine (Pandemrix) was offered to the
Norwegian population, and approximately 1.9 million
people (39.25 % of the population) were vaccinated. We
used information on GBS, pandemic influenza infection
and vaccination from nationwide health data-bases. The
aim was to estimate the associations between pandemic
influenza A(H1N1)pdm09 infection or vaccination and
GBS including all residents in Norway in the study
population.
Methods
Data sources
We linked data from several national registries and health
data-bases by using the unique 11-digit personal identifi-
cation number provided to all Norwegian residents.
Information on GBS diagnoses during the period
2009–2012 were obtained from the Norwegian Patient
Register (NPR) [15]. This is an administrative database to
which all Norwegian hospitals and outpatient clinics report
to receive governmental reimbursement. Diagnoses are
reported according to the World Health Organization’s
International Classification of Diseases, Version 10 (ICD-
10). The first registration of GBS (ICD-10 code G61.0) in
the NPR for each patient was used in the analyses.
Information on vaccinations was obtained from the
Norwegian Immunisation Register [16]. In Norway, the
Pandemrix vaccine was offered to the whole population.
Notification of pandemic influenza vaccinations was
mandatory during the influenza pandemic in 2009.
The Norwegian Directorate of Health reimburses con-
sultations in emergency outpatient clinics and general
practice. We used information on dates of physician con-
sultations for those receiving an influenza diagnoses in the
International Classification of Primary Care, second edition
(ICPC-2) code system.
We also obtained information on laboratory confirmed
pandemic influenza infections from the Norwegian
Surveillance System for Communicable Diseases [17].
This registry is a nationwide system for surveillance of
infectious diseases.
Individuals with the ICPC-2 code R80 (influenza like
illness) registered during the pandemic peak in Norway
(October 1, 2009, through December 31, 2009) or regis-
tered with a positive laboratory test for pandemic influenza
were considered as exposed to pandemic influenza
infection.
Study population
The study population included the entire Norwegian resi-
dents as registered in the National Population Registry per
October 1, 2009 (N = 4,832,211).
Statistical analysis
The pandemic peak in Norway occurred between October
1, and December 31, 2009 [18]. The vaccination campaign
began on October 19, 2009, and about 97 % of the pan-
demic vaccinations were administered before December
31, 2009. Two approaches were used to assess the risk of
GBS following pandemic influenza infection or vaccina-
tion. First, a Cox proportional-hazards regression was ap-
plied, with number of days since October 1, 2009 as the
time metric. Vaccination status and influenza diagnosis
were included as time-varying covariates. Crude and ad-
justed hazard ratios (HRs) of GBS, with 95 % confidence
intervals (CIs) were estimated using a 42-day risk window
after pandemic vaccination or influenza infection. Thus,
patients were considered as exposed only during the first
42 days after vaccination or influenza infection. The risk
window of 42-days was chosen to facilitate comparisons
with other studies. Sex and year of birth (categorized as
\1980 and C1980) were considered as potential con-
founders and were included in the adjusted analyses.
The population was followed until diagnosis of GBS,
death, emigration or end of follow-up (December 31,
2012), whichever occurred first.
In addition to the Cox regression models, a self-con-
trolled case series (SCCS) method was applied. In the
SCCS model, cases serve as their own control by com-
paring the individual risk of disease within a defined ex-
posure window, to the individual risk in other time periods
[19]. An advantage with this method is that time-constant
confounding is eliminated. Only information from exposed
cases was used, and the applied observation time was the
complete study period of 4 years; 2009–2012. The SCCS
approach was applied in three separate models. In model I,
we estimated the risk of being hospitalized with GBS
during the pandemic peak (October 1, 2009 through De-
cember 31, 2009). The incidence rate ratios (IRRs) of GBS
in the pandemic peak were compared with the risk of GBS
outside this period. In model II and model III, we estimated
IRR of GBS in a 42-day risk window following either a
diagnosis of pandemic influenza or after vaccination. The
IRRs were calculated using conditional Poisson regression.
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All analyses were performed using the Stata 13 software
(StataCorp. 2013. Stata Statistical Software: Release 13.
College Station, TX: StataCorp LP.).
Results
During 2009–2012, 490 individuals were diagnosed with
GBS in Norway (Fig. 1). There were 410 cases of GBS
diagnosed on or after October 1, 2009 (Table 1), of which
46 cases occurred during the pandemic peak (October 1,
2009 through December 31, 2009). The incidence of GBS
was 2.7 per 100,000 person-years. Figure 1 shows the
observed number of GBS cases in 3-month intervals di-
agnosed between January 1, 2009 and December 31, 2012.
The highest number of new cases occurred during the
pandemic peak. Figure 2 shows the age distribution of
patients registered with GBS. The mean age at diagnosis
was 50.4 years with a standard deviation of 21.8 years. The
majority of GBS cases (83.67 %) were observed among
individuals born before 1980.
Two individuals were diagnosed with GBS within the
42-day risk window after a physician diagnosis of in-
fluenza, and eight individuals were hospitalized with GBS
within 42 days after pandemic vaccination. Cox propor-
tional-hazards regression analyses showed that influenza
infection was associated with a higher risk of GBS in both
the crude (HR 4.22, 95 % CI 1.01–17.59) and the adjusted
analyses (HR 4.89, 95 % CI 1.17–20.36). The risk of GBS
after influenza vaccination was neither statistically sig-
nificant in the crude (HR 1.07, 95 % CI 0.49–2.35) nor the
adjusted analyses (HR 1.11, 95 % CI 0.51–2.43) (Table 2).
The IRR of GBS during the pandemic peak (model I)
was significantly elevated when compared with the other
periods (IRR 1.46, 95 % CI 1.08–1.98) (Table 3). The IRR
of GBS in a 42-day risk window following a diagnosis of
influenza (model II) was also significantly elevated (IRR
6.54, 95 % CI 1.48–28.97), whereas the association be-
tween pandemic vaccination and risk of GBS (model III)
was not statistically significant (IRR 1.12, 95 % CI
0.55–2.26).
Discussion
In this population-based study of GBS in Norway, we
found an incidence rate of 2.7 per 100,000 person-years.
By using national data-bases, we found an increased risk of
GBS during the pandemic peak, supported by an increased
risk of GBS in those diagnosed with influenza infection.
Vaccination was not significantly associated with an in-
creased risk of GBS.
Strengths and weaknesses
A major strength of the current study was the availability of
national health data from the whole Norwegian population
of more than 4.8 million individuals. By using data bases
from primary care and emergency outpatient visits for the
whole country, we had the unique opportunity to study not
only the impact of pandemic vaccination, but also pan-
demic influenza infection. To our knowledge, few other
studies have addressed risk of GBS according to both ex-
posures [3, 12–14].
The Norwegian health care system is financed through
governmental funding. All hospitalizations are free of
charge while primary care consultations and emergency
outpatient visits for persons aged 16 years or older are
charged a minor fee and physicians are reimbursed by the
government. We believe that registration of new cases of
GBS is likely to be complete. However, GBS is a rare
disease and consequently challenging to study its asso-
ciations with rare exposures.
The vaccination register in Norway is one of very few
that contains nationwide data on pandemic vaccinations.
Notifications of all administered doses were mandatory
during the pandemic, and registrations are nearly complete.
As Norway had relatively high vaccination coverage in the
general population (39.25 %), we had the opportunity to
study a rare outcome, such as GBS, after vaccination.
Previous studies on GBS following the 2009 pandemic
were mainly based on case–centre designs (collaborations
between various health centres) [3], records collected from
selected hospitals [6, 20, 21], or a case–control design [14].
These studies are therefore prone to biases from selection
of participants, the methods of collecting information and
recall bias. Many studies have been limited to a few
counties or states [21, 22].
Fig. 1 Observed number of Guillain-Barre´ syndrome (GBS) cases
per 3 month intervals from January 1, 2009 through December 31,
2012
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A major strength of the current study is that our data was
collected from the entire population prospectively and
recorded independently of each other, eliminating differ-
ential reporting and selection bias. Although GBS is a rare
disease and the number of GBS cases after pandemic
vaccination in Norway was low, it is however comparable
to previous studies [8, 9].
One weakness in this study is the under-reporting of
influenza infections. It has been estimated that around
30 % of the Norwegian population had clinical influenza
during the pandemic [23], while less than 3 % of the
population were diagnosed with influenza by a primary
care physician. The low number of consultations can be
explained by public recommendations during pandemic
peak. Due to high demands on health clinics during the
pandemic peak, people were advised not to seek medical
help for influenza symptoms if they were not in need of
urgent care or were at high risk of complications. Conse-
quently, many people with influenza were regarded as
unexposed which may have led to an underestimation of
the association between influenza infection and GBS.
Therefore, we estimated the risk of GBS during the period
of pandemic peak, in addition to estimating the risk after
receiving a physician diagnosis of influenza. Risk of GBS
was significantly elevated during the pandemic peak rela-
tive to other time periods and supported by the elevated
Table 1 Characteristics of the study population, all residents in Norway as of October 1, 2009
Nr. of individuals
(%)
Nr. of individuals vaccinated
with Pandemrix (%)
Nr. of individuals with an
influenza diagnosis (%)
Nr. of Guillain-Barre´ syndrome
cases (per 100,000 individuals)
Total 4,832,211 (100) 1,896,455 (39.25) 119,291 (2.47)a 410 (8.49)
Sex
Male 2,412,286 (49.92) 864,727 (35.85) 54,285 (2.25) 226 (9.37)
Female 2,419,925 (50.08) 1,031,728 (42.63) 65,006 (2.69) 184 (7.60)
Year of birth
\1980 3,007,831 (62.24) 1,155,428 (38.41) 54,999 (1.83) 331 (11.01)
C1980 1,824,380 (37.76) 741,027 (40.62) 64,292 (3.52) 79 (4.33)
Nr Number
a Of which 10.2 % had a positive laboratory test for pandemic influenza
Fig. 2 Observed number of patients with Guillain-Barre´ syndrome
(GBS) during the time period 2009–2012 by age at diagnosis in
5-year categories
Table 2 Hazard ratio (HR) of Guillain-Barre´ syndrome (GBS) for the
period October 1, 2009 through December 31, 2012, with associated
95 % confidence interval (CI) within a 42-day risk window after an
influenza diagnosis or vaccination; estimated by Cox proportional-
hazards regression, using the resident Norwegian population as of
October 1, 2009 (n = 4,832,211) as study population
Nr. of GBS casesa Person-year Incidence rate per 1000 person-year Crude Adjustedb
HR (95 % CI) HR (95 % CI)
Influenza diagnosis No 407 5,621,223,110 0.03 (0.02–0.03) 1 1
Yes 2 5,234,754 0.14 (0.04–0.56) 4.21 (1.01–17.59) 4.89 (1.17–20.36)
Vaccination No 401 5,546,081,387 0.03 (0.02–0.03) 1 1
Yes 8 80,376,477 0.04 (0.02–0.07) 1.07 (0.49–2.35) 1.11 (0.51–2.43)
Nr number
a Follow-up of one subject ended on October 1, 2009, giving a follow-up time of 0 days. Hence, he/she was excluded from the Cox regression
analysis
b The model is adjusted for sex and year of birth. Influenza diagnosis and vaccination were simultaneously included in the adjusted model
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risk found in those diagnosed with influenza by a
physician.
Comparison to the literature
In accordance with results from several other studies [3, 8,
9, 14, 20], we did not find an increased risk of GBS after
vaccination against pandemic influenza in Norway. While
some studies show a lack of association between GBS
following influenza A (H1N1) vaccination [3, 8, 9, 14, 20],
an increased risk of GBS following pandemic vaccination
has been reported in other studies [5, 6, 21, 22]. Many of
these studies, however, did not address influenza infection
as a risk factor for GBS.
One American study reported no significant increase in
risk of GBS within a risk period of 6 weeks after influenza
vaccine; however, a statistically significant association
between risk of GBS and antecedent infection was found
[3]. Similar lack of associations with vaccinations was
reported from an Australian study [20], British studies [8,
9] and from a European multinational case–control study
[14]. In the latter study, the analyses were adjusted for
influenza-like illness/upper respiratory tract infection and
seasonal influenza vaccine.
In contrast, a meta-analysis study from the USA re-
ported a modest increased risk of GBS after 2009 influenza
A (H1N1) vaccination [5]. A Canadian study showed a
small but significant increase in the number of GBS cases
after mass influenza vaccination in Quebec [21] and a study
from Germany on the Pandemrix vaccine reported a sta-
tistically significant association between GBS and vacci-
nation in a 5–42 days risk window [6]. Unlike other
studies, an American study by Vellozzi et al. [22] sug-
gested a protective effect of influenza A (H1N1) vaccina-
tion. Vellozzi et al. showed that at the end of the influenza
season, the cumulative risk of GBS was lower among
vaccinated than among unvaccinated individuals.
Conclusion
This population-based study confirmed that GBS is a rare
disease. Risk of GBS was significantly higher during the
pandemic season relative to other time periods. Our results
support that pandemic influenza increased the risk of GBS.
Pandemic vaccination was not associated with an increased
risk of GBS. In our study, a small number of individuals
were diagnosed with GBS after a diagnosis with pandemic
influenza infection or vaccinations and the results should
be interpreted with caution.
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